ZONG-HAN YAOWEI-YU LIAOCHAO-CHI HOKUAN-YU CHENJIN-YUAN SHIHJIN-SHING CHENZHONG-ZHE LINChia-Chi LinCHIH-HSIN YANGCHONG-JEN YU2022-09-152022-09-1520171083-7159https://www.scopus.com/inward/record.uri?eid=2-s2.0-85029699677&doi=10.1634%2ftheoncologist.2016-0331&partnerID=40&md5=9e43d2571b88aa3797e7aabd7b416766https://scholars.lib.ntu.edu.tw/handle/123456789/620280BACKGROUND: This study aimed to identify independent prognostic factors for overall survival (OS) of patients with advanced non-small cell lung cancer (NSCLC) harboring an activating epidermal growth factor receptor (EGFR) mutation and receiving gefitinib as first-line treatment in real-world practice. MATERIALS AND METHODS: We enrolled 226 patients from June 2011 to May 2013. During this period, gefitinib was the only EGFR-tyrosine kinase inhibitor reimbursed by the Bureau of National Health Insurance of Taiwan. RESULTS: = .211, respectively). CONCLUSION: HCV infection, performance status (ECOG ≥2), newly diagnosed advanced NSCLC without prior operation, and liver metastasis predicted poor OS in EGFR mutation-positive advanced NSCLC patients treated with first-line gefitinib; however, neither BM at initial diagnosis nor intracranial progression during gefitinib treatment had an impact on OS. IMPLICATIONS FOR PRACTICE: The finding that chronic hepatitis C virus (HCV) infection might predict poor overall survival (OS) in epidermal growth factor receptor mutation-positive advanced non-small cell lung cancer (NSCLC) patients treated with first-line gefitinib may raise awareness of benefit from anti-HCV treatment in this patient population. Brain metastasis in the initial diagnosis or intracranial progression during gefitinib treatment is not a prognostic factor for OS. This study, which enrolled a real-world population of NSCLC patients, including sicker patients who were not eligible for a clinical trial, may have impact on guiding usual clinical practice.[SDGs]SDG3journal article10.1634/theoncologist.2016-0331285072062-s2.0-85029699677